An observational study in Early Childhood Caries, sponsored by Aydin Adnan Menderes University. Completed at 1 site in Turkey. Open to participants aged 3 Years to 70 Months. Per ClinicalTrials.gov, last updated 2021-10-21.
Sponsored by Aydin Adnan Menderes University · Observational
This study aimed to evaluate the levels of interleukin 10, interleukin 6, interleukin 32 and tumor necrosis factor-alpha (TNF-α) in saliva of children with early childhood caries.
Fifty six children ( 28 with early childhood caries and 28 without early childhood caries ; age range 3-6 years) will be recruited for the study. Probing pocket depth (PPD), gingival index (GI) and plaque index (PI) will be recorded and saliva samples will be collected. Interleukin-32, Interleukin-10, Interleukin-6 and TNF-α will be analyzed in saliva samples by ELISA.
477 studies on the registry are indexed under Necrosis; 54 are open to participants now.
This study's enrollment of 58 is below the median of 100 across 147 observational studies indexed under Necrosis.
Browse Necrosis studies →Aydin Adnan Menderes University is the lead sponsor of 236 studies on the registry; 54 are open to participants now.
Counted across the registry records on this site, refreshed daily.
28 children with early childhood caries and 28 children without caries will be collected.
Exclusion Criteria:
Early chilhood caries group
Diagnostic Test: ELISA
Control group
Diagnostic Test: ELISA
Enzim linked immunoabsorbant assay
IL-32
Interleukin- 32 level
Time frame: Baseline
IL-10
Interleukin- 10 level
Time frame: Baseline
IL-6
Interleukin- 6 level
Time frame: Baseline
Tnf-Alpha
Tnf-alpha level
Time frame: Baseline
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Aydin Adnan Menderes University